Glycomine

We are developing a PMM2-CDG substrate replacement therapy. GLM101 is a mannose-1 phosphate treatment.

Latest funding

$115M Series B+ · May 9, 2025

Led by Advent Life Sciences · Source: fundraisingfox.com

Total raised: $195M across 3 sourced rounds

All 3 rounds ↓

Website: glycomine.com.

X: @GlycomineBio · 52 followers.

LinkedIn: linkedin.com.

Category: Health and bio.

Sectors: Biotechnology, Pharmaceutical, Therapeutics.

Stage: Series B+.

Based in: San Carlos, United States.

Founded: 2014.

Total raised: $195M in 3 sourced rounds.

Last round: May 9, 2025 · 552 days ago.

Headcount: 11–50 employees.

On Recent Funding since: Nov 8, 2026.

Signals

X account@GlycomineBio · created Jun 15, 2021 (5 years old) · 52 followers

Website registeredMay 26, 2013 (13 years old)

TIMELINE · MONEY RAISED

Glycomine | 3648 days on the record

@GlycomineBio·Raised $195M in 3 sourced rounds

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

May 9, 2025
Series B+ · $115M
AAdvent Life Sciences (lead), CCTI Life Sciences Fund (lead), AAbingworth, AAsahi Kasei Corporate Venture Capital, CChiesi Ventures, NNovo Holdings, RRemiges Ventures, RRiverVest, SSanderling Ventures, SSanofi Ventures
Source: fundraisingfox.com
June 23, 2021
Series B+ · $68M
AAbingworth (lead), SSanofi Ventures (lead), AAsahi Kasei, CChiesi Ventures, MMission BioCapital, NNovo Holdings, RRemiges Ventures, RRiverVest, SSanderling Ventures
Source: businesswire.com
June 15, 2021
X account created
November 16, 2016
Series A · $12M
CChiesi Ventures (lead), SSanderling Ventures (lead), MMesa Verde Venture Partners
Source: fiercebiotech.com
May 26, 2013
Website created

Founders and team

AR
Agnes Rafalko Founder

LinkedIn
PM
Peter McWilliams CEO
DF
Deirdre Foley Director of R&D, Biology
RM
Rose Marino Chief Medical Officer
SA
Steven Axon Chief Executive Officer

Investors

Companies like Glycomine

AAspen Neuroscience$115M Series B+ · Nov 2025
QQuit With JonesSeed · Jan 2025
RRemedium$10M Series A · Aug 2026
HHandspring Health$19M Series B+ · Jul 2026
LLatus Bio$97M Series A · May 2026
SScience&Humans$10M Series A · Jan 2026

Other companies backed by Advent Life Sciences

TT-Therapeutics$133M Series B+ · Nov 2026
EEpitopea$31M Series A · Oct 2024
FF2G$100M Series B+ · Sep 2024
AArgá Medtech$58.72M Series B+ · Feb 2024
PProximieSeries B+ · Sep 2024

Advent Life Sciences portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/glycomine (get a free API key).